Sight-threatening retinopathy is associated with lower mortality in type 2 diabetic subjects: A 10-year observation study

Diabetes Research and Clinical Practice

Volumn 77, Issue 1, 2007, Pages 141-147

  Lövestam Adrian, Monica ^a   Hansson Lundblad, Catarina ^a   Torffvit, Ole ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Macrovascular complications; Mortality; Retinopathy; Type 2 diabetes

Indexed keywords

ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; RETINA MACULA EDEMA; RISK FACTOR; STROKE; SWEDEN;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; SWEDEN; VISION DISORDERS;

EID: 34247164588     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.10.026     Document Type: Article

References (30)

1. Krolewski A.S., Czyzy A., Janeczko D., and Kopczynski J. Mortality from cardiovascular disease among diabetics. Arch. Ophthalmol. 13 (1977) 345-350
2. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., and Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall Study. BMJ 287 (1983) 867-870
3. Moss S.E., Klein R., and Klein B.E. Cause-specific mortality in a population-based study of diabetes. Am. J. Public Health 81 (1991) 1158-1162
4. U.K. Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
5. U.K. Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
6. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352 (1998) 837-853
7. Early Treatment Diabetic Retinopathy Study Research Group. Associations of Mortality and Diabetes Complications in Patients with Type 1 and Type 2 Diabetes, ETDRS report number 27. Diab. Care 28 (2005) 617-625
8. Davis M.D., Hiller R., Magli Y.L.M., et al. Prognosis for life in patients with diabetes: relation to severity of retinopathy. Trans. Am. Ophthalmol. Soc. 77 (1979) 144-170
9. Klein R., Klein B.E.K., and Moss M.A. Age related eye disease and survival: The Beaver Dam Eye Study. Arch. Ophthalmol. 113 (1995) 333-339
10. Klein R., Klein B.E.K., Scot E., Moss M.A., and Cruickshanks K.J. Association of ocular disease and mortality in a diabetic population. Arch. Ophthalmol. 117 (1999) 1487-1495
11. Torffvit O., and Agardh C.D. Treatment mode and development of diabetic complications. A 10-year observation study of 385 type 2 diabetic patients. Diab. Res. 35 (2000) 117-125
12. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS report number 1. Arch. Ophthalmol. 103 (1985) 1796-1806
13. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS report number IV. Int. Ophthalmol. Clin. 27 (1987) 265-275
14. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical applications of Diabetic Retinopathy Study (DRS) findings: DRS report number 8. Ophthalmology 88 (1981) 583-600
15. Lövestam-Adrian M., Agardh E., and Agardh C.D. The temporal development of retinopathy and nephropathy in type 1 diabetes mellitus during 15 years diabetes duration. Diab. Res. Clin. Pract. 45 (1999) 15-23
16. Wong T.Y., Klein R., Couper D.J., et al. Retinal microvascular abnormalities and incident strokes. The atherosclerosis risk in communities study. Lancet 358 (2001) 1134-1140
17. Wong T.Y., Klein R., Sharrett A.R., et al. Retinal arteriolar narrowing and incident coronary heart disease in men and women. The atherosclerosis risk in communities study. JAMA 287 (2002) 1153-1159
18. Fuller J., Stevens L., and Wang S.L. the WHO Multinational study group. Risk factors for cardiovascular mortality and morbidity: The WHO multinational study of vascular disease in diabetes. Diabetologia Suppl. 2 (2001) S54-S64
19. Ono T., Kobayashi J., Sasako Y., et al. The impact of diabetic retinopathy on long-term outcome following coronary artery bypass graft surgery. J. Am. Coll. Cardiol. 7 40 (2002) 428-436
20. Klein R., Klein B.E.K., Moss S.E., Davis M.D., and DeNets D.L. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch. Ophthalmol. 107 (1989) 244-249
21. Donnelly R., Yeung M.J., and Manning G. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J. Hypertens. Suppl. 1 (2003) 7-12
22. Owens D., Volund A., Jones D., et al. Reinopathy in newly presenting non-insulin-dependent (Type II) diabetic patients. Diab. Res. 9 (1988) 59-65
23. U.K. Prospective Diabetes Study (UKPDS) Group. Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis, UKPDS 50. Diabetologia 44 (2001) 156-163
24. U.K. Prospective Diabetes Study (UKPDS) Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus, UKPDS 69. Arch. Opthalmol. 122 (2004) 1631-1640
25. Estacio R.O., Jeffers B.W., Gifford N., and Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diab. Care 23 Suppl. 2 (2000) B54-B64
26. Garg R., et al., Collaborative Group on ACE Inhibitor. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
27. Yusuf S., Lonn E., Bosch J., and Gerstein H. Summary of randomized trials of angiotensin converting enzyme inhibitors. Clin. Exp. Hypertens. 21 (1999) 835-845
28. Torffvit O., and Agardh C.D. The impact of metabolic and blood pressure control on incidence and progression of nephropathy. A 10-year study of 385 type 2 diabetic patients. J. Diab. Compl. 15 (2001) 307-313
29. Pradhan R., Fong D., March C., Jack R., Rezapour G., Norris K., et al. Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients. A pilot study. J. Diab. Compl. 16 (2002) 377-381
30. Chaturvedi N., et al., EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351 (1998) 28-31